Abstract 95P
Background
Primary cardiac tumors are rare with an incidence of 0.018%, having poor prognosis and 25% of them malignant. Surgical treatment is the mainstay of definitive therapy. Most studies on cardiac sarcomas have limited numbers, deal with specific histopathological variants and provide limited information on clinical outcomes. Most research studies on primary cardiac sarcoma are case reports or literature reviews. So our aim is to add additional evidence for the management of Cardiac Sarcoma with systemic therapy and evaluate the impact of adjuvant chemotherapy versus Radiotherapy on survival outcome.
Methods
We used Surveillance, Epidemiology and End Results (SEER) program software to extract the data of 109 patients with Cardiac Sarcoma diagnosed from 2000-2019. We divided them into two subgroups according to the treatment modality; adjuvant chemotherapy and adjuvant Radiotherapy. We used SPSS 23 for data analysis. Kaplan-Meier curve, Log-rank test for survival analysis.
Results
The 3-year and 5-year relative survival was 22.9% and 8.2%respectively. The mean age is 44.87 and standard Deviation is 17.647. Out of 109 cases, 82.5 % were treated with adjuvant chemotherapy and 17.5% received adjuvant Radiotherapy with overall 5-year survival outcome for both treatment regimens (8.7%, 6.5% respectively; P=0.730). Performing Cox-regression analysis for the predictors: Age, Race, Sex, Treatment and year of diagnosis. Age is the only predictor with statistical significance on survival (P = 0.022, HR=1.015 95% CI: 1.002-1.029).
Conclusions
This study has a large sample compared to the other studies about this rare type. The results show primary cardiac sarcoma had poor 5-year survival rate and adjuvant chemotherapy had quiet similar survival outcome compared to adjuvant Radiotherapy. So the best treatment option depends on the final evaluation of each patient according to benefit-risk ratio and age consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.